

OPIOID MEDICATIONS REFERENCES

1. De Vries TJ, Shippenberg TS. [Neural systems underlying opiate addiction.](#) *J Neurosci.* 2002;22(9):3321-3325.
2. Borg L, Kreek MJ. [The pharmacology of opioids.](#) In: *In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine.* Vol 3. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
3. Xi ZX, Stein EA. [GABAergic mechanisms of opiate reinforcement.](#) *Alcohol Alcohol.* 2002;37(5):485-494.
4. Dahan A, Yassen A, Romberg R, et al. [Buprenorphine induces ceiling in respiratory depression but not in analgesia.](#) *Br J Anaesth.* 2006;96(5):627-632.
5. American Psychiatric Association. [Substance-Related and Addictive Disorders.](#) APA. 2013.
6. Kosten TR, George TP. [The neurobiology of opioid addiction: implications for treatment.](#) *NIDA Sci Pract Perspect.* 2002;1(1):13-20.
7. Henry JA. [Metabolic consequences of drug misuse.](#) *Br J Anaesth.* 2000;85(1):136-142.
8. SAMHSA/CSAT. [Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction.](#) 2004.
9. Volkow N. [NIDA-supported science leads to first FDA-approved medication for opioid withdrawal.](#) *NIDA.* 2018.
10. FDA. [FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults.](#) 2018.
11. National Drug Intelligence Center (NDIC). [Intelligence Bulletin: Buprenorphine: Potential for Abuse.](#) 2004.
12. SAMHSA. [Protracted withdrawal.](#) *SAMHSA Advis.* 2010;9(1).
13. 21 USC § 812. [Schedules of controlled substances.](#) 2012.
14. Johnson RE, Strain EC, Amass L. [Buprenorphine: how to use it right.](#) *Drug Alcohol Depend.* 2003;70(suppl 2):S59-S77.
15. FDA. [Medication Guide: Butrans™ CIII \(buprenorphine\) Transdermal System.](#) 2010.
16. Labelle CT, Han SC, Bergeron A, et al. [Office-Based Opioid Treatment with Buprenorphine \(OBOT-B\): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.](#) *J Subst Abuse Treat.* 2015;15.
17. Kraus ML, Alford DP, Kotz MM, et al. [Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction.](#) *J Addict Med.* 2011;5(4):254-263.
18. BioDelivery Sciences International. [Bunavail prescribing information.](#) 2014.
19. Stanton A, McLoed C, Luckey B, et al. [SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program.](#) 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.

20. Walsh SL. [Clinically Relevant Pharmacology of Buprenorphine](#). 2009.
21. SAMHSA. [Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update](#). Winter 2016.
22. Huestis MA. [High-dose buprenorphine in humans](#). In: *In: Kintz P, Marquet P, Eds. Buprenorphine Therapy of Opiate Addiction*. Vol Totowa, NJ: Humana Press, Inc; 2002.
23. Chiang CN, Hawks RL. [Pharmacokinetics of the combination tablet of buprenorphine and naloxone](#). *Drug Alcohol Depend*. 2003;70(suppl 2):S39-S47.
24. Tzschentke Thomas M. [Behavioral Pharmacology of Buprenorphine, with a Focus on Preclinical Models of Reward and Addiction](#). *Psychopharmacology (Berl)*. 2002;161(1):1-16. doi:10.1007/s00213-002-1003-8.
25. Donaher PA, Welsh C. [Managing opioid addiction with buprenorphine](#). *Am Fam Physician*. 2006;73(9):1573-1578.
26. SAMHSA. [Substance Use Disorders](#). *SAMHSA Website*. 2014.
27. Kahan M, Srivastava A, Ordean A, et al. [Buprenorphine: new treatment of opioid addiction in primary care](#). *Can Fam Physician*. 2011;57(3):281-289.
28. Yokell MA, Zaller ND, Green TC, et al. [Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review](#). *Curr Drug Abuse Rev*. 2011;4:28-41.
29. Durand F, Valla D. [Assessment of prognosis of cirrhosis](#). *Clin Pharmacokinet*. 2008;28(1):110-122.
30. Mendelson J, Jones RT. [Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?](#) *Drug Alcohol Depend*. 2003;70(2S):S29-S37.
31. Renner J, Saxon A, Levounis P. [Buprenorphine Update and Evolving Standards of Care](#). IPS: The Mental Health Services Conference. October 2015. New York City.
32. Kissin W, McLeod C, Sonnefeld J, et al. [Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence](#). *J Addict Dis*. 2006;25(4):91-103.
33. Alford DP, Labelle CT, Kretsch N, et al. [Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience](#). *Arch Intern Med*. 2011;171(5):425-431.
34. Arfken CL, Johanson CE, di Menza S, et al. [Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians](#). *J Subst Abuse Treat*. 2010;39(2):96-104.
35. Mintzer IL, Eisenberg M, Terra M, et al. [Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings](#). *Ann Fam Med*. 2007;5(2):146-150.
36. FDA. [FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder](#). November 2017.
37. FDA. [FDA approves first buprenorphine implant for treatment of opioid dependence](#). *FDA News Events*. May 2016.
38. Reckitt Benckiser Pharmaceuticals Inc. [Suboxone Prescribing Information](#). 2014.
39. Farney RJ, McDonald AM, Boyle KM, et al. [Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone](#). *Eur Respir*. 2013;42:394-403.

40. Lintzeris N, Clark N, Muhleisen P, et al. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence. 2001.
41. FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. *FSMB Website*. 2013.
42. Weiss RD, Potter JS, Fiellin DA. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. *Arch Gen Psychiatry*. 2012;68(12):1238-1246.
43. Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Intern Med*. 2014;174(12):1947-1954.
44. Dunn KE, Sigmon SC, Strain EC. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. *Drug Alcohol Depend*. 2011;119(1-2):1-9.
45. Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know?. *Am J Addict*. 2010;19(1):73-88.
46. Kao Ming-Chih, Zheng Patricia, Mackey Sean, et al. Trends in Benzodiazepine Prescription and Co-Prescription with Opioids in the United States, 2002--2009. AAPM Annual Meeting, July 2014.
47. ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
48. Stein DJ, Isper JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev*. 2006;1:CD002795.
49. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study. *Biol Psychiatry*. 2008;63(6):629-632.
50. Drugs.com. Doxazosin. *Drugs.com*. November 2015.
51. McNicholas LF. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar; 2011.
52. Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS). 2013.
53. NIAAA. Alcohol Facts and Statistics. NIAAA. 2015.
54. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. *Am J Drug Alcohol Abuse*. 2011;37(1):1-11.
55. APA. Focus on Marijuana: Current Risks and Controversies. *Am Psychiatr Assoc Webinar*. 2012.
56. McCance-Katz EF. Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid-Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents. *Clin Infect Dis*. 2005;41(suppl 1):S89-95.
57. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. *Curr HIV/AIDS Rep*. 2010;7(3):156-160.
58. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. *Drug Alcohol Depend*. 2007;91(2-3):269-278.

59. Herve S, Riachi G, Noblet C, et al. [Acute hepatitis due to buprenorphine administration](#). *Eur J Gastroenterol Hepatol*. 2004;16(10):1033-1037.
60. Saxon AJ, Ling W, Hillhouse M, et al. [Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial](#). *Drug Alcohol Depend*. 2013;128:71-76.